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ROLE OF VAV2 IN PODOCYTE INFLAMMASOME ACTIVATION AND GLOMERULAR 
INJURY DURING HYPERHOMOCYSTEINEMIA 
 
By Sabena M. Conley 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2016 
 
Major Director: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology 
 
Hyperhomocysteinemia (hHcys) is a widely known pathogenic factor in the progression of end-
stage renal disease (ESRD) and it is also associated with an increased risk for injurious 
cardiovascular pathologies during ESRD. HHcys is linked to the formation and activation of the 
NOD-like receptor protein 3 (NLRP3) inflammasome, characterized as a critical early mechanism 
initiating the inflammatory response. NADPH oxidase (NOX)-derived reactive oxygen species 
(ROS) mediate the activation of the NLRP3 inflammasome in podocytes in response to elevated 
levels of homocysteine (Hcys) in vitro and in vivo. However, it remains unknown how NLRP3 
inflammasome activation is triggered by NOX. The aim of the present study sought to determine 
the signaling cascade that triggers glomerular injury and sclerosis during hHcys mediated by Vav2, 
XV 
 
a guanine nucleotide exchange factor (GNEF). Using both genetic and pharmacological 
interventions of Vav2, we first tested whether this GNEF is involved in hHcys-induced NLRP3 
inflammasome activation in podocytes by its role in activation of the Rac-1-NOX complex. 
Further, we explored whether pharmacological targeting of Vav2 activation may regulate NLRP3 
inflammasome signaling pathway during hHcys-induced glomerular injury. We found that mice 
with hHcys (on the FF diet) or oncoVav2 (a constitutively active form of Vav2) transfection in the 
kidney exhibited increased colocalization of NLRP3 with apoptosis-associated speck-like protein 
(ASC) or caspase-1 and elevated IL-1β levels in glomeruli, indicating the formation and activation 
of the NLRP3 inflammasome. This glomerular NLRP3 inflammasome activation was 
accompanied by podocyte dysfunction and glomerular injury, even sclerosis. Local transfection of 
Vav2 shRNA plasmids significantly attenuated hHcys-induced NLRP3 inflammasome activation, 
podocyte injury, and glomerular sclerosis. In cultured podocytes, Hcys treatment and oncoVav2 
transfection increased NLRP3 inflammasome formation and activation. This NLRP3 activation 
was inhibited by Vav2 shRNA, associated with reduction of Rac-1 activity and ROS production. 
Administration of NSC23766, a Rac-1 inhibitor substantially attenuated inflammasome formation, 
desmin expression and decreased podocin expression in glomeruli of hHcys mice. These results 
suggest that elevated Hcys levels activate Vav2 and thereby increase NOX activity, leading to 
ROS production. ROS trigger NLRP3 inflammasome activation, podocyte dysfunction and 
glomerular injury. Therefore, the present study defines a novel mechanism underlying hHcys-
induced NLRP3 inflammasome activation and its progression to ESRD. 
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CHAPTER ONE 
INTRODUCTION 
Hyperhomocysteinemia (hHcys) is recognized as a significant contributor to the 
development of glomerular dysfunction; if left untreated eventually, hHcys-associated glomerular 
injury can progress into consequent end-stage renal disease (ESRD). It has been reported that the 
molecular mechanisms mediating the pathogenic action of hHcys is dependent on nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase (NOX), which generates the primary enzymatic 
product, superoxide (O2
.-). NOX-derived oxidative stress has been associated with the initiation 
and progression of glomerular diseases including diabetic nephropathy, hHcys-induced 
nephropathy, hypertension and obesity-related kidney diseases 1. It is imperative to understand 
how this cascade of glomerular injury is instigated and amplified during redox signaling. In this 
regards, the regulation of NOX activation is dependent on Rac-1 GTPase activity, in which 
activated Rac stimulates the aggregation of the NOX complex as a functional enzyme to produce 
O2
.-. Vav2, a guanine nucleotide exchange factor may be key in Rac-1 activation.  
The nucleotide-binding oligomerization domain Nod-like receptor containing pyrin domain 
3 (NLRP3)-centered inflammasome has been well characterized as a redox sensor that turns on the 
inflammatory response and instigates damage in the glomeruli, ultimately leading to glomerular 
sclerosis. Activation of the NLRP3 inflammasome is considered ubiquitous in different organs and 
cells and is a potent intracellular inflammatory machinery that proteolytically cleaves interleukin-
1β (IL-1 β) or IL-18 into their active forms 2–4. Some investigators believed that this inflammasome 
activation may be the root of many chronic degenerative diseases. In the kidney, the formation and 
activation of the NLRP3 inflammasome plays a critical role in a broad spectrum of glomerular and 
tubulointerstital diseases as well as tubular injury and repair. Inhibition of this complex may serve 
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as an innovative therapeutic strategy to possibly prevent or treat glomerular diseases associated 
with inflammation.  
1.1 Hyperhomocysteinemia 
HHcys has been identified as one of the leading pathogenic factors in the progression of 
ESRD and it is also associated with an increased risk for cardiovascular complications. Amongst 
the growing prevalence of chronic kidney disease (CKD), hHcys is a prevalent comorbidity 
occurring in 85% of diagnosed patients 5. At present there are no diagnostic biomarkers for 
accurately predicting these group of patients and with the prolonged clinical silence, it is a 
challenge to completely reverse due to the functional abnormalities already present that develops 
into fibrosis. The early mechanisms responsible for increased homocysteine (Hcys) levels during 
ESRD or other associated kidney diseases still remain unclear. Prior studies have demonstrated 
that a reduction in glomerular filtration rate (GFR) contributes to the increases in both serum 
creatinine and Hcys 6–8. Elevated concentrations of Hcys leads to endothelial damage and 
dysfunction that progress into a buildup of extracellular matrix proteins, ultimately inducing renal 
glomerular sclerosis and atherosclerosis 9–11. It has become increasingly evident that hHcys may 
result in glomerular degenerative diseases mainly through podocyte dysfunction and injury similar 
to other metabolic disorders such as diabetes mellitus, where glomerular pathological 
modifications will develop even in the absence of initiating factors. 
More than 40 years ago, Dr. Kilmer S. McCully reported that elevated plasma Hcys level is 
a key factor in the pathogenesis of cornary artery disease 9. Through extensive epidemiological 
studies, high plasma Hcys has been implicated in numerous other conditions throughout the body 
such as cardiovascular diseases 12–14 , stroke 15, neurodengerative diseases 16 and ESRD 7,17,18. 
   
  
 
3 
 
Patients with ESRD often develop hHcys with total blood Hcys (tHcys) levels of three times higher 
than the normal range of < 10 μmol/L 19.  
1.1.1 Homocysteine Metabolism 
The kidney is a major participant in the homeostatic balance of amino acids and protein 
metabolism; however, alterations in glomerular function have been closely linked with defective 
synthesis, degradation or clearance, diet deficiencies and uremic cardiovascular complications 
19,20.  
A basic illustration of the Hcys metabolic pathway is presented in Figure 1. Hcys is a 
methionine-containing essential amino acid synthesized from food or the metabolism of 
endogenous proteins. Following two separate enzymatic reactions methionine is converted into S-
adenosyl methionine (SAM), a universal methyl donor for neurotransmitters, nucleic acids, 
hormones and phospholipids. Demethylation of SAM yields S-adenosyl homocysteine (SAH) 
which is hydrolyzed to form Hcys and adenosine as byproducts. At this phase in the metabolic 
pathway, Hcys serves as a key regulatory molecule that can undergo remethylation or 
transsulfuration to maintain a balance in Hcys concentrations  19,21. If Hcys is remethylated back 
to methionine by methionine synthase (MS), folate and cobalamin (vitamin B12) are required 
cofactors. Alternatively, Hcys can undergo transsulfuration to cystathionine by cystathionine β-
synthase (CBS), in an irreversible pyridoxal-5'-phosphate (vitamin B6) dependent reaction. 
Cystathionine is then degraded into cysteine and converted into sulfates which are released in the 
urine. 
Normally 75% of total Hcys is covalently bound to a protein molecule, whereas the 
remaining fraction is freely filtered through the glomeruli 21. Disturbances in Hcys metabolism 
have been linked to the progressive loss of kidney function, endothelial dysfunction and 
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atherogenesis 22. HHcys-associated nephropathy orginates from defective clearance of Hcys in the 
plasma. There is an increasing body of evidence indicating that age, smoking, coffee consumption 
and folate antagonist may also affect Hcys concentrations 21. In addition, alterations in enzymatic 
activity and cofactors necessary for proper synthesis and catabolism have been associated with 
overwhelmingly elevated plasma Hcys levels.  
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Figure 1. Homocysteine Metabolism. 
Initially, dietary methionine is converted to S-adenosyl methionine (SAM); releasing of a methyl 
group converts SAM to S-adenosylhomocysteine (SAH) by the enzyme SAH hydrolase. 
Following hydrolase, SAH forms adenosine and Hcys. Once formed, Hcys then can be 
remethylated into methionine by methylenetetrahydrofolate reductase (MTHFR) or degraded by 
cystathione β-synthase (CBS) and γ-cystathionase. 
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1.1.2 Models of Hyperhomocysteinemia in Animals 
Initial studies led by Dr. Kilmer S. McCully revealed children with mental retardation, 
accelerated growth during childhood, dislocated ocular lenses and thrombosis were found to 
excrete Hcys in the urine as well as advanced arteriosclerosis 9,23. Through careful review of these 
clinical cases, Dr McCully discovered inherited abnormalities of the enzymes controlling 
homocysteine levels in these patients. Several animal models of hHcys have been developed to 
examine the effects of altered Hcys metabolism in the development of organ dysfunction and 
progression of disease. Elevated Hcys concentrations can be induced by diet, gene knockouts or a 
combination of both to investigate the causal role of Hcys in vivo. Dietary approaches include 
addition of methionine to the diet; reducing the dietary content of vitamin B6 which prevents the 
conversion of Hcys to cystathionine; limiting the remethylation of Hcys by implementing a diet 
deficient in folate and/or vitamin B12 or adding Hcys directly to the drinking water 
24. Modulations 
of these factors in vivo have direct relevance to human disease progression, since low levels of 
these vitamins are commonly seen in patients with hHcys. Additionally, hHcys can be induced by 
deletion of CBS, MTHFR or MS, targeting of these enzymes in the Hcys metabolism pathway 
mimic the inborn errors seen in patients with severe hHcys (Hcys > 100 μmol/L).  
1.2 NAPDH Oxidase in the Kidney 
An ever growing body of work has characterized the numerous intrarenal enzymatic systems 
that contribute to the generation of reactive oxygen species (ROS). These sources include xanthine 
oxidases, lipoxygenases, cyclo-oxygenases (COXs), P450 mono-oxygenases, mitochondrial 
respiratory chain and NOX 25. However, the latter is considered the predominant source of O2
.- in 
the kidney 26. Assembly of both membrane-associated (gp91phox and p22phox) and cytosolic 
(p47phox, p40phox, and p67phox) subunits activates this complex, resulting in the shift of electrons to 
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molecular oxygen, leading to the generation of O2
.- 25,27,28. Initial studies using a rodent model of 
spontaneous hypertension reported upregulation of all NOX subunits localized in the renal cortex 
29. In addition, all components of the NOX complex have been documented to be prominently 
expressed throughout the kidney including areas such as the renal vessels, tubules, interstitium and 
glomeruli 30.  
Under normal circumstances, ROS are short-lived species that are rapidly metabolized by 
scavenging antioxidant enzymes. Low levels of ROS generated by NOX participate in normal 
physiologic processes such as intracellular signaling as second messengers 31, mediating hormonal 
effects 32,33, regulating ion channel activity, oxygen sensing 34, adipocyte differentiation 35, gene 
expression 31,36, reproduction 37, as well as cell growth, senescence, and apoptosis 38,39. More 
specifically, NOX-derived ROS are implicated in various physiological regulation in the kidney. 
For example, the kidney maintains glucose homeostasis by participating in gluconeogenesis 
(production of glucose to glutamine) in proximal tubular cells and reabsorbing filtered glucose into 
the blood 28. Type II diabetes is a chronic systematic disorder metabolically characterized by 
elevated levels of glucose. Winiarska et al. demonstrated that pretreatment of apocynin, a known 
NOX inhibitor reduced tubular cell gluconeogenesis in a diabetic rabbit model, indicating the 
importance of NOX regulation during diabetic conditions in order to maintain glucose balance 40. 
In addition, tubuloglomerular feedback is a crucial mechanism which regulates the hemodynamic 
response upon alterations in tubular salt overload in the kidney 28. Production of O2
.- leads to 
constriction of the afferent arteriole 41 and scavenging of nitric oxide in the macula densa 42. 
However, silencing of NOX and apocynin treatment inhibited high salt-induced O2
.- generation 42. 
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1.2.1 Pathophysiological Role of NADPH Oxidase in the Kidney 
During pathological conditions, renal NOX has been connected to oxidative stress and 
disease progression. Metabolic disruptions in the kidney leads to increased renal NOX expression, 
resulting in overproduction of ROS which disrupts the homeostatic balance and causes injurious 
consequences by altering the structure and function of various lipids, proteins and DNA. 
Generation of ROS exceeds the normal catabolism processes affecting the concentration in the 
kidney. 
We have documented that NOX-induced oxidative stress is crucial in the pathophysiological 
role of renal injury associated with hHcys 43,44. Podocytes, known as the structural framework of 
the glomerular filtration barrier are the most susceptible targets of injury in a number of renal 
diseases. Following injury, podocytes become effaced, detached from the basement membrane and 
undergo hypertrophy and apoptosis. We observed protection of podocyte structure and function in 
gp91phox gene KO mice when they were exposed to hHcys 44. These mice exhibited significantly 
attenuated proteinuria, foot process effacement and podocyte loss compared to their wild-type 
counterparts. Additionally, inhibition of the gp91phox gene in cultured podocytes prevented Hcys-
induced O2
.- generation. We have also shown that NOX redox signaling mediates hHcys-induced 
inflammasome activation inducing glomerular inflammatory injury and consequently leading to 
glomerular sclerosis 43. Altogether, we have determined that podocyte ROS generation is an early 
mechanism mediating hHcys-induced glomerulosclerosis. NOX-derived ROS generation is a 
common observation related to other renal-associated pathologies including diabetes and 
hypertension 30. During focal and segmental glomerulosclerosis, the transient receptor potential 
cation channel-6 (TRPC6) co-localizes with NOX to form a lipid raft signaling complex with the 
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podocyte specific protein, podocin, producing a localized burst of ROS that may modulate the 
podocyte morphology and function 28.  
1.2.2 Role of Rac-1 GTPase in NADPH Oxidase Regulation 
During the NOX activating process, the major regulatory step necessary for activation of 
NOX involves heterodimerization of gp91phox and p67phox mediated by the Rac protein. Rac-1 
GTPase has been reported to rotate between two conformational states either a GDP-bound 
“resting” state or GTP-bound “active” state. The transition between these two confirmations is 
regulated by either GTPase activating proteins (GAPs), which stimulate the intrinsic GTPase 
activation causing the switch to the resting condition or guanine nucleotide exchange factors 
(GNEFs) that facilitate the exchange of GDP for GTP. Conversion to activated Rac-1 initiates the 
translocation of the cytosolic subunits to the membrane, resulting in the formation of a functional 
NOX complex 45,46. It has been reported that the Vav subfamily represents distinct GNEFs with 
high specificity to Rac-mediated NOX activation 47–49. It is possible that the activation of Vav2 
through elevated Hcys accelerates the switch from GDP to GTP, thereby enhancing NOX activity 
and O2
.- production.  
1.3 NLRP3 Inflammasome in the Glomeruli 
Both microbial and non-microbial inflammation has been reported to participate in 
glomerular inflammatory responses, which may represent a critical pathogenic mechanism 
responsible for glomerular injury and subsequent ESRD. In particular, the non-microbial 
inflammation is widely recognized as a key pathological mechanism that mediates or promotes the 
development of glomerular sclerotic pathology during ESRD associated with several common 
systemic diseases such as hypertension, hHcys, diabetes mellitus, and erythematosus lupus 50,51 . 
In this regard, activation of inflammatory responses in the residential renal cells may be critical in 
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initiating glomerular injury and renal dysfunction. There is evidence that glomerular IL-1β is 
mainly generated from podocytes, but not other cell types. Increased IL-1β production from 
podocytes are critically involved in the progression of many non-proliferative forms of 
glomerulonephritis and other glomerular diseases induced by local inflammatory processes in 
humans and rodents 52–54. Using different approaches, our recent studies have shown that the 3 
major NLRP3 components were indeed enriched in murine podocytes and that their assembling 
into a multiprotein complex in podocytes occurs during stimulations by various danger factors 
such as L-Hcys, uric acid crystals, and adipokine-visfatin 51,55. It has been proposed that NLRP3 
inflammasome activation may importantly contribute to the onset or gradual progression of 
glomerular injury under different pathological conditions 51,56,57.   
1.3.1 NLRP3 inflammasome 
Originally, the NLRP3 inflammasome was identified as a crucial player necessary for 
activation of caspase-1, and the primary function is to activate cysteine proteases that subsequently 
induce inflammatory responses in tissues or organs by generation of pro-inflammatory interleukins 
(ILs) 23. It is known that there are 23 Nod-like receptor (NLR) genes in the human genome 
including the NLRP family that contains a pyrin domain and the NLRC family that contains a 
caspase recruitment domain. Among all NLRs, only a few can be assembled into the 
inflammasome to activate caspases 58, which are NLRP1, NLRC4, and NLRP3 inflammasomes. 
NLRP1 was the first identified inflammasome, and it was found to provide immunity against 
bacterial cell wall components, which directly activates caspase-5 without ASC (apoptosis-
associated speck like protein with a caspase recruitment domain) 59,60. The presence of ASC, 
however, greatly accelerates NLRP1 inflammasome activity 60. Another NLR-associated 
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inflammasome is NLRC4, and its activation is only triggered by bacterial flagellin and endogenous 
cell cytoplasmic components 61–63.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The NLRP3 inflammasome has been well characterized and its activation strongly links to 
sterile inflammation in a variety of chronic degenerative diseases 64. The NLRP3 gene was first 
found to have mutations in patients with familial cold urticaria (FCU) and Muckle-Wells syndrome 
(MWS) 65. Consequently, the over exuberant inflammatory response seen in these patients was 
attributed to an NLRP3-dependent mechanism that results in defective apoptosis and 
transcriptional regulation. Further studies in these MWS patients demonstrated that they 
spontaneously secrete active IL-1β, which is due to the interaction of NLRP3 with the ASC protein. 
This interaction was later recognized as the formation of the NLRP3 inflammasome 66. Over the 
last 5 years, many bacterial and viral pathogen-associated molecular patterns (PAMPs) and danger-
associated molecular patterns (DAMPs) released from damaged tissues or cells have been 
identified as activators of the NLRP3 inflammasome. Tremendous efforts have been made 
worldwide to address the possible role of this inflammasome in the initiation or development of 
different diseases and to find inducers or activators of the NLRP3 inflammasome under different 
pathological conditions, which may help identify therapeutic targets for treatment of related 
diseases.  
1.3.2 NLRP3 inflammasome activators 
There are a very diverse range of danger factors that initiate activation of the NLRP3 
inflammasome through different mechanisms. It has been reported that microbes such as the 
influenza virus, adenoviruses, Staphylococcus aureus, E. coli, Neisseria gonorrhoeae, and 
Candida albicans may stimulate NLRP3 inflammasome activation 67–72. One of the mechanisms 
activating the NLRP3 inflammasome during infections of these microorganisms may be associated 
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with the formation of pannexin-1 channel that permits the entry of these microbial toxins into the 
cytoplasm. In addition, monosodium urate (MSU) crystals, aluminum salts, silica or asbestos are 
also reported to stimulate the NLRP3 inflammasome 2,73,74 and as non-microbial materials they are 
phagocytosed into the cell leading to lysosomal damage, triggering NLRP3 inflammasome 
activation to produce IL-1β and other cytokines. Additionally, extracellular ATP and potassium 
were shown to induce NLRP3 assembly and activation, which may be mediated by the purinergic 
P2X7 receptor and pannexin-1 75.  
NLRP3 formation and activation have been originally attributed to auto-inflammatory 
diseases and more than 20 such auto-inflammatory diseases can be treated by inhibition of NLRP3 
activation and by antagonizing the action of IL-1β. Recently, many studies found that the 
activation of the NLRP3 inflammasome also contributes to the development of various chronic 
metabolic diseases such as diabetes mellitus, gout, silicosis, and obesity. In addition, in acute 
myocardial infarction, atherosclerosis, glomerular sclerosis, Alzheimer’s disease and liver 
cirrhosis the NLRP3 inflammasome is also shown to be activated 51,76–78. In this regard, 
accumulation of the amyloid-β protein in the brain is considered as an activator of the NLRP3 
inflammasome to promote local inflammation or cell injury leading to the development of 
Alzheimer’s disease 79. In addition, the high levels of IL-1β have been detected in the brains of 
patients suffering from Alzheimer’s disease. During atherosclerosis, cholesterol crystals or even 
oxidative products of cholesterol may serve as a danger factor to cause phagolysosomal damage, 
activating the NLRP3 inflammasome and thereby promoting a pro-atherosclerotic phenotype in 
arteries 80. In addition, trauma and excessive exercises may produce some chemokines that may 
activate the NLRP3 inflammasome. This process may be associated with hyaluronan-mediated 
cellular responses 81.  
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In a murine model of diabetes, hyperglycemia stimulated NLRP3 inflammasome activation, 
subsequently causing injury to pancreatic islet cells, glucose intolerance and insulin resistance 82. 
Recent findings in our lab demonstrated that Hcys can stimulate NLRP3 inflammasome formation 
and activation in different types of cells, if it is increased in blood or extracellular space. In 
endothelial cells, this NLRP3 inflammasome activation will lead to endothelial dysfunction and 
induce atherogenic effects. In podocytes, increased activation of the NLRP3 inflammasome results 
in local glomerular inflammation and podocyte injury or transformation, ultimately leading to 
glomerular sclerosis 51. We have shown that inhibition of the NLRP3 inflammasome via genetic 
or pharmacological interventions prevented Hcys-induced podocyte injury and glomerular 
sclerosis 51. We also demonstrated that the adipokine, visfatin instigates vascular inflammation 
and injury by activation of the NLRP3 inflammasome, which ultimately leads to atherosclerosis 
81. To our knowledge, increasing numbers of danger factors including PAMPs and DAMPs are 
reported as activators of the NLRP3 inflammasome under different pathological conditions. 
Therefore, the NLRP3 inflammasome is evolving as a new common pathogenic mechanism for 
different diseases, in particular, those chronic degenerative diseases associated with inflammatory 
pathology.  
 1.3.3 Mechanisms Mediating NLRP3 Inflammasome Activation 
Detection of pathogenic microorganisms and sterile stressors, recruitment of ASC, caspase-
1 cleavage and production of inflammatory molecules are the main steps directing the pathological 
path to NLRP3 inflammasome activation. Given that more than 120 substrates were predicted for 
caspase-1, it is predictable that its maturation or activation will produce a variety of biological 
responses in addition to production of cytokines. However, IL-1β and IL-18 are well-studied 
products from the NLRP3 inflammasome. It is now known that the production of various cytokines 
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via activation of caspase-1 triggers the inflammatory response and other cellular activities 83. In 
phagocytes, the NLRP3 inflammasome activation follows a tightly regulated intracellular 
signaling and regulatory process, which include two important steps. Initially, NF-κB initiates the 
increased expression of genes encoding for inflammasome formation such as NLRP3, pro-caspase-
1, pro-IL-1β and pro-IL-18 4. This initial step is referred to as “priming”, which is influenced by a 
cellular disturbance that activates pattern recognition receptors (PRRs). Signal II involves the 
detection of PAMPS or DAMPs by NLRP3, which promotes the recruitment of the inflammasome 
components to form the molecular complex 4. Aggregation of these molecules together leads to 
the cleavage of pro-caspase-1 into two subunits, p10 (10 kDa) and p20 (20 kDa), and active 
caspase-1 is the heterodimer 23. Considerable evidence has indicated that the regulation of 
inflammasome activity can be controlled by transcription of NLRP3 via signaling cytokine 
receptors 84. Additionally, tight transcriptional regulation through microRNA, miR-223, influences 
inflammasome activation by manipulating NLRP3 mRNA levels 85,86. In some other cells 
including endothelial cells, podocytes, neurons, epithelial cells and hepatic stellate cells, however, 
a sustained and small scale inflammasome activation may not require the priming step. Several 
signaling pathways have been reported to account for activation of the NLRP3 inflammasome. 
Among them, potassium (K+) efflux, ROS generation, and cathepsin B leakage into the cytosol 
due to phagolysosomal rupture are often studied 87. For example, an intracellular surge of K+ ions 
into the cellular milieu is capable of triggering NLRP3 inflammasome activation. This model of 
activation occurs when extracellular ATP interacts with gated cation channels like P2X7R or 
bacterial toxins to produce pore formation 70,88. Researchers have shown experimentally that  
reduction of high K+ concentrations in cells diminishes the activation of the inflammasome, 
although this molecular mechanism has not been characterized in all K+ efflux inflammasome 
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inducers 89–91. It has been reported that many inflammasome activators stimulate production of 
ROS and these activators could be exogenous stimuli such as microbes or endogenously produced 
or secreted molecules including DAMPs, Hcys and uric acids 92. Uptake of particulate and 
crystalline matter is reported to cause disruption of the lysosomal compartment causing cathepsin 
B release that may lead to NLRP3 inflammasome activation 74,79,93.  
In recent studies, we have demonstrated that during hHcys podocyte injury and glomerular 
sclerosis are consequences of NLRP3 inflammasome activation 43,51,56. We found that this 
activation is associated with NOX-derived O2
-. and related oxidants 43,94. Chemical scavengers and 
pharmacological inhibitors of ROS were used to confirm that elevated plasma Hcys may serve as 
a DAMP that activates the NLRP3 inflammasome in podocytes, which leads to podocyte 
dysfunction, glomerular injury, inflammation and ultimate glomerular sclerosis 56. It has been 
suggested that DAMPs like Hcys, cholesterol, or visfatin may increase NOX activity via 
membrane raft clustering to form lipid raft redox signaling platforms in podocytes or glomerular 
endothelial cells, thereby producing O2
.-. NLRP3 can sense and monitor intracellular redox 
changes. If intracellular O2
.- increases, it dissociates  from thioredoxin-interacting protein (TXNIP) 
and then binds to ASC, forming the NLRP3 inflammasome 56 where IL-1β, IL-18 and high 
mobility group box 1 (HMGB1) are produced. These factors, in particular, IL-1β act to recruit 
inflammatory cells to the glomeruli, in which O2
.- and additional cytokines are generated, creating 
a chronic sterile inflammatory cascade that contributes to glomerular injury and sclerosis. 
Excessive amounts of active caspase-1 and IL-1β or other inflammasome products may reduce the 
level of podocyte-specific proteins, nephrin and podocin, which will result in slit diaphragm 
derangement and proteinuria. These inflammasome products may also directly induce podocyte 
pyroptosis, consequently reducing podocyte numbers and causing foot process effacement 43,51,57.  
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1.3.4 Effector Response of Inflammasome Activation 
There is substantial evidence that activation of the NLRP3 inflammasome turns on 
inflammatory responses, which may influence the progression to many chronic degenerative 
disease including CKDs by eliciting damaging insults independent of inflammation 95. This 
NLRP3 inflammasome activation can cause both inflammatory and non-inflammatory effects 96. 
In this regard, there is evidence that activated caspase-1 may act on more than 120 substrates and 
that pyroptosis, enhanced glycolysis and lipid metabolism, altered cell survival and many other 
direct effects during NLRP3 inflammasome activation may influence cell function and associated 
metabolism. It is believed that the physiological or pathological role of activated NLRP3 
inflammasome extends far beyond inflammation 97. 
With respect to the classical pathway, various cellular proteins such as cytokines or 
chemokines may be produced and secreted during NLRP3 inflammasome activation, which is 
associated with an internal signal or amino-terminal that direct their translocation from the 
endoplasmic reticulum (ER) lumen. These factors produced during inflammasome activation are 
then actively transported to the Golgi complex, packaged into vesicles, fusing with the plasma 
membrane and excreted out of the cells 98,99. Fibroblast growth factor 2 (FGF2), galectin 1 and 3 
as well as mature IL-1β and the DAMPs including HMBG1 have been documented to be released 
during NLRP3 inflammasome activation. These secreted factors induce inflammatory, cell 
survival and repair reactions by activating cell surface receptors including FGF receptor-1, the IL 
receptors, and the receptor for advanced glycation end-products (RAGE) 97. Among these 
cytokines or chemokines, IL-1β and IL-18 are often studied over the current years. Both have 
extensive biological activities that result in the onset and development of inflammation as well as 
in the disturbance of cell functions. Moreover, IL-1α, may also contribute to the inflammatory 
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process. IL-1α, is released from necrotic cells and further processing of this interleukin is not 
necessary because it descends from an active precursor 100. Interestingly, some recent studies have 
indicated that almost all inflammasome activators are able to induce co-secretion of IL-1α with 
other interleukin molecules 101. However, IL-α release is not directly from the NLRP3 
inflammasome activation, but may be dependent upon intermediate reactions after inflammasome 
activation 4.  
Pyroptosis, a specialized form of cell death serves as a non-inflammatory or non-canonical 
effector mechanism during NLRP3 inflammasome activation. It is caspase-1 mediated and 
proceeds independently of pro-inflammatory cytokine production. This form of cell death 
enhances the immune responses by exposing foreign agents to the immune system’s surveillance 
102. Cytoplasmic swelling, osmotic lysis and release of intracellular molecules into the outside of 
the cell are all characteristics of pyroptosis 97. Although attempts have been made to fill the gaps 
in knowledge of pyroptosis, characterization of its molecular features still remains under debate. 
A distinctive characteristic that may contribute to the pathogenesis of organ failure include the 
abnormal overexpression of collagen leading to fibrosis 103. With the initial insult often unknown 
in fibrosis, this form of wound healing can cause high mortality rates and proceed independent of 
inflammation 103. In addition to pyroptosis, many other non-canonical effects induced by activation 
of the NLRP3 inflammasomes or consequently enhanced caspase-1 activity include enhanced 
glycolysis, abnormal cellular lipid metabolism, disturbance of cell survival programs, or altered 
cell membrane permeability. These non-inflammatory effects may also contribute to the functional 
and structural pathology of NLRP3 inflammasome activation in a variety of chronic degenerative 
diseases. 
   
  
 
18 
 
1.4 NLRP3 Inflammasomes in Glomerular Diseases 
Growing evidence reveal that pathological progression of many kidney diseases originates 
from inflammation as a result of renal injury. Routes to resolving renal damage involves activation 
of transmembrane and intracellularly expressed PRRs as well as induction of transcriptional 
inflammatory mediators that are crucial in the innate immune response and cellular homeostasis 
104,105, which may be reflected by the activation of the NLRP3 inflammasome. In the subsequent 
section, we highlighted some evidence showing the implications of this inflammasome in the onset 
or development of several different glomerular diseases.  
1.4.1 Chronic glomerulonephritis (GN) 
Chronic GN is referred to as inflammation of the glomeruli, which develops over several 
years with no or very few symptoms, but causes irreversible kidney damage, ultimately leading to 
ESRD. In GN, infiltrating mononuclear phagocytes generate canonical NLRP3 inflammasome 
signaling, and the activation of NLRP3 inflammasomes also occurred in some non-immune 
glomerular cells such as podocytes and glomerular capillary endothelial cells 52–54. There is 
evidence that in a rodent model of nephrotoxic serum nephritis (NTN) IL-1 and tumor necrosis 
factor (TNF) are critical in promoting glomerular injury by interaction with the IL-1 receptor  (IL-
1R) 106. Inflammasome signaling components were upregulated during NTN, in particular, in renal 
dendritic cells, which led to increased production of mature IL-1β. In Nlrp3 and Asc gene knockout 
mice having NTN, glomerular injury and related inflammatory responses such as leukocyte 
infiltration or T-cell activation were significantly attenuated compared to their wild type 
littermates. Interestingly, reduced secretion of active IL-1β was only observed in Asc knockout 
mice, but not in Nlrp3-deficient mice, suggesting another potential molecular mechanism to be 
involved, which is independent of the NLRP3 inflammasome. Additionally, NLRP3 may have 
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non-canonical early inflammatory effects in NTN, which may be associated with glomerular 
release of the inflammatory protein, HMGB1 in a NLRP3-mediated manner. This HMGB1 is 
currently considered as one of the important mediators to promote the non-canonical functions of 
NLRP3/ASC inflammasome activation 106.   
Acute and chronic inflammatory responses have also been considered as an important 
pathogenic mechanism of lupus nephritis (LN). Participation of the NLRP3 inflammasome may 
promote the progression of LN 107. Recent studies have demonstrated that a selective inhibitor of 
NLRP3 inflammasome activity, Bay11-7082, prevented assembling and activation of the 
inflammasome and thereby decreased proteinuria, blood urea nitrogen, and glomerular damage 
during LN. Accompanied with these beneficial effects, Bay11-7082 treatment also decreased renal 
immune complex deposition and lowered the level of glomerular IL-1β, TNF-α and chemokine 
(C-C Motif) ligand 2 (CCL2). The infiltration of macrophages was also found to be significantly 
reduced. However, other studies have shown that active caspase-1 and renal secretion of pro-
inflammatory cytokines such as IL-1β were not significant during acute heterologous NTN and 
other glomerulonephritis 108. It is clear that more studies are needed to further establish the 
contribution of this inflammasome and other related molecular mechanisms in GN.   
1.4.2 Hyperhomocysteinemic nephropathy  
HHcys is characterized as a Hcys level that exceeds 15 µmol/L in the plasma of patients. 
Elevated plasma Hcys levels have been linked to the progression of many chronic systemic 
diseases including hypertension, peripheral vascular disease, Alzheimer’s disease, diabetes and 
atherosclerosis 109. In regard to renal disease, hHcys is considered one of the important pathogenic 
factors leading to the progression of ESRD. Additionally, the development of cardiovascular 
complications related to ESRD has also been attributed to hHcys 48. Increasing evidence has 
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indicated that glomerular injury and ultimate sclerosis during chronic hHcys proceeds in a manner 
independent of hypertension. Accumulation of Hcys in plasma or hHcys was shown to result in 
the glomerular pathology including extracellular matrix accumulation and podocyte injury. Some 
studies demonstrated that the inability of Hcys to be properly cleaned or degraded from blood 
eventually leads to compromised renal function and glomerulosclerosis 110,111.  Although the 
mechanism remains unclear on how Hcys causes cellular injury and sclerotic changes in many 
organs and tissues, inflammatory cytokines were found increased in blood and many tissues during 
hHcys. It has been indicated that the inflammation and related molecular machinery, 
inflammasomes, may play a crucial role in these processes 112,113. Under some pathological 
conditions, Hcys-induced glomerular injury was indeed found to activate local inflammatory 
responses by enhancing the production of monocyte chemoattractant protein 1 in glomerular 
mesangial cells and tubular epithelial cells 114. Inhibition of the inflammatory process could 
significantly protect the kidney against hHcys-associated damage 114.  
However, it remains poorly understood how the inflammation in glomeruli during hHcys is 
activated and whether this is associated with NLRP3 inflammasome formation and activation. Our 
recent studies revealed that treatment of glomerular epithelial cells (podocytes) with Hcys induced 
the NLRP3 inflammasome, forming molecular complex and producing IL-1β and other cytokines. 
This NLRP3 inflammasome activation critically contributes to the development of glomerular 
sclerosis during hHcys. Moreover, there is evidence that knocking out of the Nlrp3 gene protected 
podocytes and glomeruli against hHcys-induced injury as observed by decreased urinary protein 
excretion, reduced glomerular damage and diminished expression of the podocyte-specific damage 
marker, desmin in a mouse model of hHcys. The Nlrp3 gene has been well documented as an 
essential component of NLRP3 inflammasomes, which serves as a sensor for monitoring redox 
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changes. This sensing function of NLRP3 is confirmed to be mediated by its association and 
dissociation with TXNIP 56.  
1.4.3 Diabetic nephropathy 
Diabetic nephropathy (DN) is the leading cause of ESRD and remains a great clinical concern 
due to high mortality and morbidity rates. Poor management of diabetes often results in the loss of 
renal function, which is due to gradual changes in the glomerular structure and associated functions 
such as thickening of the basement membrane, mesangial expansion, proteinuria/albuminuria and 
glomerular fibrosis. DN is different from other types of glomerular diseases that result in ESRD, 
and it is generally categorized as a non-inflammatory glomerular disease. However, recent 
genome-wide transcriptome analysis revealed that several inflammatory signaling pathways are 
present or activated during DN. Although some reports have shown hyperglycemia-induced cell 
death and immune cells accumulation in glomeruli, an inflammatory response, the precise 
mechanisms by which inflammation is activated during DN remains to be elucidated 115.  
More recent studies have now suggested that infiltration of inflammatory cells is crucial in 
the pathogenesis of DN 116. IL-1β and IL-18 secreted from immune cells and glomerular resident 
cells such as podocytes, endothelial cells or mesangial cells may possibly promote DN 51,54,117. 
Initial studies from Shahzad et al 117 revealed that diabetic mice have upregulated expression of 
inflammasome molecules and pro-inflammatory cytokines in circulation when compared to their 
non-diabetic counterparts. Morphological and progressive functional changes were also observed 
in the kidney of these diabetic mice. In the db/db mouse model of diabetes, however, 
transplantation of Nlrp3 and caspase-1 deficient mice bone marrow did not attenuate the kidney 
damages compared to control db/db mice, suggesting that blocking of myeloid-lineage immune 
cells is insufficient in preventing the progression to DN. In other studies, the production of 
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mitochondrial ROS was shown to initiate NLRP3 inflammasome activation in diabetic conditions, 
further establishing the causative link between NLRP3 inflammasome activation and DN. In 
addition, inhibition of NLRP3 or caspase-1 in the kidney led to protective outcomes seen by 
inactivation of the inflammasome. This provides a strong foundation in how the NLRP3 
inflammasome serves as an important mediator for pro-inflammatory cytokine production by 
caspase-1 activation and how inhibition of this complex formation may serve as a promising 
approach to treat DN. With respect to the mechanism responsible for NLRP3 inflammasome 
activation, it has been reported that high glucose (HG) treatment in mice induced NOX activity 
triggering NLRP3 inflammasome activation in glomerular podocytes and leading to podocyte 
injury during DN. However, inhibition of TXNIP by shRNA and its inhibitors abolished this DN-
induced inflammasome activation 118. Since deletion of mouse Nlrp3 gene, antagonism of IL-1R 
and inhibition of mitochondrial ROS production all were shown to protect or even reverse DN in 
mice, targeting the NLRP3 inflammasome has been indicated to serve as a beneficial strategy for 
treatment of DN 117.   
1.4.4 Glomerular injury and sclerosis in obesity 
CKD is now considered as one of the strongest risk factors for the morbidity and mortality 
in obese patients, with the prevalence of obesity increasing worldwide 119,120. Previous studies have 
identified visceral fat as a generator of bioactive substances that contribute to the pathophysiologic 
and structural changes in glomeruli 121. Mechanistically, obesity-induced glomerular sclerosis and 
ultimate ESRD is involved in chronic inflammation, abnormal glomerular vascular remodeling, 
rise in renal plasma flow, hyperfiltration and renal lipotoxicity 122. 
Most recently, we have indeed shown that the NLRP3 inflammasome is implicated in the 
development of obesity and associated chronic glomerular injury. It serves as an important 
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initiating mechanism to activate local glomerular inflammation leading to ultimate glomerular 
sclerosis in obese mice 57. Inhibition of the Asc gene significantly protected mice from high fat 
diet (HFD)-induced obesity, podocyte damage and glomerular injury. Although the molecular 
mechanism of HFD-induced inflammasome activation remains unknown, it is possible that 
increased production of fatty acid metabolites, ceramide and palmitate is a key trigger. There is 
evidence that the abundance of fatty acid metabolites in adipose tissue positively correlates with 
the development of obesity and type II diabetes in mice. In this regard, Vandanmagsar et al 123 
showed that supplement of ceramide to adipose tissue explants led to NLRP3-dependent caspase-
1 activation and IL-1β production, suggesting that ceramide acts a danger signal to stimulate the 
NLRP3 inflammasome. We have also shown that a HFD increased the glomerular ceramide 
production due to the activation of acid sphingomyelinase, a ceramide producing enzyme. The 
increased ceramide production induced the formation and activation of NLRP3 inflammasome in 
glomeruli, which contributes to the obesity-induced glomerular injury. All these results have 
indicated that the NLRP3 inflammasome may also be a therapeutic target for obesity and related 
glomerular injury and sclerosis.  
1.5 The NLRP3 Inflammasome as a Therapeutic Target in Chronic Glomerular Diseases 
The prolonged period of clinical silence in chronic glomerular disease or CKD leads to 
irreversible pathological damage leading to glomerular fibrosis. It has been well known that early 
detection of these alterations and abnormalities in the impaired kidneys is necessary to facilitate 
therapeutics that can improve clinical outcomes. Management of risk factors such as hypertension, 
increase blood glucose level and albuminuria has been vital in slowing the progression to ESRD. 
Although current treatments including angiotensin converting enzyme inhibitors (ACEi), 
angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists and statins 124 have 
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been used clinically for many years, the morbidity and mortality of CKD patients still remain high. 
It is obvious that identification of new therapeutic targets and development of new strategies for 
treatment of ESRD are imperative.  
There is growing interest in administering anti-inflammatory therapies to halt renal and 
cardiovascular functional loss, for example, targeting oxidative stress and inflammatory responses. 
However, these therapies are met with a bit of skepticism and may only elicit partial improvements 
in the pathogenic process of CKD characterized by glomerular sclerosis. The root of glomerular 
dysfunction and other renal diseases previously associated with inflammation may potentially be 
eliminated by inhibiting NLRP3 inflammasome activation. Convincing evidence has shown that 
by blocking this complex there is a reduction in tissue and cellular inflammation. Because this 
strategy targets both the non-inflammatory and non-canonical damaging effects on cell function 
and metabolism, it may be more efficient during glomerular diseases. Indeed, treatments with IL-
1β antibodies have proven very effective in patients with cyropyrin-associated periodic syndromes 
(CAPS) 125.  
Activation of the NLRP3 inflammasome following MSU and other crystal-induced 
pathologies translate into the disease manifestation of gout or pseudogout 2. There is also evidence 
that antagonism of the IL-1 signaling pathway immediately improved the clinical outcome of 
patients with these arthropathic diseases 126,127. However, whether crystal-associated 
nephropathies have the similar mechanisms has yet to be established. To our knowledge, approved 
inhibitors of IL-1β are commercially available for treatment of various inflammasome-mediated 
autoinflammatory diseases; however, they produced adverse effects at the injection site 128,129. 
Anakinra, a recombinant IL-1R antagonist competitively inhibits IL-1 signaling 130, and 
administration of Anakinra has been reported to improve the inflammatory response in 
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hemodialysis patients 131. In addition, Glyburide, commonly used to treat type II diabetes, was 
found to block chloride and potassium channels in pancreatic β cells to regulate insulin release 132. 
This compound is able to inhibit IL-1β release upon stimulation with LPS in human monocytes 
133, but it does not block capsase-1 activation unless Nlrp3, NF-κB or P2X7 genes are knocked out 
in mice 134–137. It is expected that more therapeutic strategies will be forthcoming. For example, 
the use of NLRP3 inhibitors and the P2X7 receptor blockers may block NLRP3 inflammasome 
activation. IL-1 and IL-18 receptor blockers, caspase-1 inhibitors can antagonize the effects of 
NLRP3 inflammasome products, and H2S donor Na2S, lysosome stabilizer, cathepsin-B inhibitors, 
and milk fat globule EGF-8 may serve as an endogenous inhibitor of inflammasome-induced IL-
1β production. These potential therapeutic strategies target different stages of NLRP3 
inflammasome formation and activation, which may be selected for the use in prevention or 
treatment of ESRD and associated glomerular diseases.  
1.6 Aims of Study 
The hypothesis to be tested in the present study states that: Vav2 associated redox signaling 
associated with NOX contributes to Hcys-induced NLRP3 inflammasome formation and 
activation, thereby causing glomerular inflammatory responses and associated pathologies. 
 
In order to test this hypothesis the following specific aims were proposed: 
1. To determine whether GNEF, Vav2 contributes to NLRP3 inflammasome activation and 
associated podocyte injury and glomerular sclerosis in vivo in hyperhomocysteinemic 
mice. 
2. To determine whether Vav2 exerts its pathogenic role by activation of the Rac-1-NOX 
complex, inducing NLRP3 inflammasome formation and activation in murine podocytes. 
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3. To investigate pharmacological targeting of Vav2 as a potential therapeutic to prevent 
CKD progression associated with hHcys-associated nephropathy.  
 
The overall hypothesis and three specific aims of this project are schematically presented in 
Figure 2. 
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Figure 2. The Overall Hypothesis. 
By inhibition and overexpression of the Vav2 gene, Aim 1 and 2 will demonstrate the role of 
Vav2 in NOX-mediated redox signaling leading to NLRP3 inflammasome formation and 
activation in podocytes. More specifically, these aims will reveal the involvement of Rac-1-NOX 
signaling in the Hcys-induced sclerotic process. Aim 3 will further elucidate if Vav2 may serve 
as a therapeutic target for termination of early events in hyperhomocysteinemic nephropathy and 
ESRD. 
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CHAPTER TWO 
GENERAL METHODS 
 
2.1 Hyperhomocysteinemic Mouse Model 
Eight week old mice on a C57BL/6J background were purchased from Jackson Laboratories 
(Bar Harbor, ME). To produce a rapid and advanced model of hHcys, mice were 
uninephrectomized and afterward allowed 1-week to recover. Uninephrectomized mice were fed 
either a normal diet (ND) or a folate-free (FF) diet to induce hHcys (Dyets Inc, Bethlehem, PA) 
for 4 weeks. Before sacrifice, 24-hour urine samples were collected using mouse metabolic cages 
and afterward blood samples were collected. The mice were then sacrificed and renal tissues were 
harvested for biochemical and molecular analysis. All protocols were approved by the Institutional 
Animal Care and Use Committee of Virginia Commonwealth University. 
2.1.1 In vivo Treatments 
For in vivo genetic studies, Vav2 short hairpin RNA (shRNA) or a dominant-active Vav2 
variant (oncoVav2) plasmid with a luciferase expression vector was co-transfected into the kidneys 
via a femoral artery injection using the ultrasound-microbubble system. Plasmid containing 
scrambled small RNA (sRNA) was used as a control. After introduction of plasmid into the kidney, 
these mice were maintained on either a ND or FF diet for 4 weeks. 
For in vivo pharmacological studies, Nlrp3 knockout (Nlrp3-/-) mice were purchased from 
the Mutant Mouse Research and Resource Center. Groups of mice received intraperitoneal (IP) 
injections of the Vav2 activator, Uridine Triphosphate (UTP) or Rac-1 inhibitor, NSC-23766 (1 
mg/kg/day) throughout the ND or FF diet feeding period, doses were chosen according to a recent 
report 138. 
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2.1.2 Ultrasound-microbubble Assisted Plasmid Transfection 
After allowing one week for recovery from uninephrectomy surgery, a preparation of 
plasmid encoding either Vav2 shRNA, oncoVav2 or the reporter gene luciferase was mixed with 
cationically charged Optison microbubbles (GE Healthcare, Piscataway, NJ) then injected into the 
femoral artery and locally transfected to the kidney by sonoporation with a continuous wave output 
of 1 MHz at 10% power output at 30 sec intervals for a total of 6 minutes. To daily monitor the 
efficiency of gene expression, mice were anesthetized with ketamine (100 mg/kg IP) and xylazine 
(10 mg/kg IP), and an aqueous solution of luciferin (150 mg/kg IP) was injected 5 minutes before 
imaging as described previously 48. The anesthetized mice were imaged using the Xenogen 
IVIS200 in vivo imaging system (Perkin Elmer, Waltham, MA). Photons emitted from luciferase-
expressing cells and transmitted through tissue layers were quantified over a defined period of 
time ranging up to 5 minutes using the software program Living Image (Xenogen) as an overlay 
on an Igor program (Wavemetrics). If transfection was not detected by in vivo imaging, the mice 
were sacrificed and experiments terminated due to unsuccessful transgene expression. 
2.2 Culture of Murine Podocytes  
A conditionally immortalized mouse podocyte cell line gifted by Dr. Paul E. Klotman 
(Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, New York, 
NY, USA) was cultured undifferentiated with 10 U/mL recombinant mouse interferon-γ at 33°C 
on collagen I-coated flasks in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
100 U/mL penicillin and 100 mg/mL streptomycin. Prior to experiments, podocytes were 
thermoshifted at 37°C for 10-14 days to differentiate in the absence of interferon-γ and afterward 
used for experiments. 
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2.2.1 In vitro Treatments 
Our previous studies have demonstrated a 40 µM treatment of L-Hcys for 24 hours to be the 
optimal concentration and time to produce a significant activation of the NLRP3 inflammasome 
43,56,107. Pharmacological interventions of Vav2 UTP (100 µM) and NSC-23766 (50 µM) were 
added to the cells 1 hour prior to Hcys treatment. Their doses for effective activation or inhibition 
were confirmed in previous studies 139,140. 
2.2.2 RNA interference 
Podocytes were transfected with a scrambled sRNA, Vav2 shRNA or constitutively active 
form of Vav2 (oncoVav2) plasmid directly to the nucleus via 4D- Nucleofector Technology 
(Lonza, Basel, Switerland). The dominant active oncoVav2 plasmid containing an N-terminal 
truncation was a generous gift from Dr. Keith Burridge from the University of North Carolina at 
Chapel Hill 141.  Small pores in the cell membrane develop temporarily through electrical impulses 
and cell-specific solutions. Substrates are then delivered through the cytoplasm and into the 
nuclear membrane. 2 x 106 podocyte cells were resuspended in SF Cell Line nucleofector solution 
containing 2 μg plasmid shRNA or DNA, transferred into a certified cuvette and placed into the 
nucleofector system. Podocytes were subjected to cell-type specific program CM-137, and then 
resuspended in pre-warmed medium in cultured plates. An additional group of podocytes was used 
to transfect Vav2 siRNA medium (Life Technologies, Carlsbad, CA) using the siLentFect Lipid 
Reagent (Bio Rad, Berkeley, CA), which was incubated in serum-free for 25 minutes according to 
the manufacturer’s instructions. After 4 hours incubation at 37ºC in both nucleo- and lipid-
transfected cells, medium was replaced with fresh serum containing medium and podocytes were 
allowed an overnight recovery prior to treatment with Hcys. 
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2.3 High Performance Liquid Chromatography (HPLC) Analysis of Plasma Hcys 
Plasma Hcys levels were measured as previously described 142 by using 100 µL plasma or 
standard solution mixed with 10 µL of internal standard, thionglycolic acid (2.0 mmol/L) then 
treated with 10 µL of 10% tri-n-butylphosphine (TBP) solution in dimethylformamide at 4°C for 
30 minutes. Then, 80 µL of ice-cold 10% trichloroacetic acid (TCA) in 1 mmol/L EDTA was 
added and centrifuged to remove proteins in the sample. 100 µL of the supernatant was transferred 
into the mixture of 20 µL of 1.55 M sodium hydroxide, 250 µL of 0.125 M borate buffer (pH 9.5), 
and 100 µL of 1.0 mg/mL ABD-F solution. The resulting mixture was incubated at 60°C for 30 
minutes to accomplish derivatization of thiols. HPLC was performed with a HP 1100 series 
equipped with a binary pump, a vacuum degasser, a thermo stated column compartment, and an 
auto sampler (Agilent Technologies, Waldbronn, Germany). Separation was carried out at an 
ambient temperature on an analytical column, Supelco LC-18-DB (1504.6 mm ID, 5 m) with a 
Supercoil LC-18 guard column (204.6 mm ID, 5 m). Fluorescence intensities were measured with 
an excitation wavelength of 385 nm and emission wavelength of 515 nm by a Hewlett-Packard 
Model 1046A fluorescence spectrophotometer. The peak area of the chromatographs was 
quantified with a Hewlett-Packard 3392 integrator. The analytical column was eluted with 0.1 M 
potassium dihydrogen phosphate buffer (pH 2.1) containing 6% acetonitrile (v/v) as the mobile 
phase with a flow rate of 2.0 mL/min. 
2.4 Confocal Microscopy and Immunofluorescence of Frozen Tissue and Cells  
To observe colocalization of inflammasome and podocyte marker proteins, indirect 
immunofluorescent staining was used in frozen tissue sections and podocytes. Podocytes seeded 
in 8-well chambers were fixed in 4% paraformaldehyde (PFA), washed with phosphate-buffered 
saline (PBS), and blocked with 1% bovine serum albumin (BSA) in PBS before being incubated 
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in primary antibodies (1:100) overnight at 4°C. The primary goat anti-NLRP3 (Abcam, 
Cambridge, MA) antibody was used in combination with the following: rabbit anti-ASC (Santa 
Cruz, Santa Cruz, CA) or rabbit anti-caspase-1 (Santa Cruz). Frozen slides with mouse kidney 
tissue were fixed in acetone, blocked with 3% donkey serum, then incubated with the same 
aforementioned primary antibodies (1:50) overnight at 4°C. Additional groups of podocytes and 
frozen kidney sections were only stained for antibodies against podocyte markers podocin (1:50; 
Sigma, St. Louis, MO), desmin (1:50; BD Biosciences, San Jose, CA) or Vav2 (Santa Cruz, Santa 
Cruz, CA). Double immunofluorescent staining was performed by Alexa-488 or Alexa-555-
labeled secondary antibodies (1:200 podocytes, 1:50 frozen kidney slides; Life Technologies, 
Grand Island, NY) with an incubation of 1 hour at room temperature. Slides were then washed, 
mounted and observed using a confocal laser scanning microscope (Fluoview FV1000, Olympus, 
Japan) and tools in Image Pro Plus 6.0 software (Media Cybernetics, Bethesda, MD) were used to 
analyze colocalization, or the degree of overlap between the two wavelengths, which was 
expressed as the Pearson Correlation Coefficient (PCC). 
2.5 Immunohistochemistry 
Kidneys were perfused in 4% PFA, removed and fixed in 10% neutral buffered formalin. 5-
μm tissue sections embedded in paraffin were cut and mounted onto microscope slides. 
Deparaffination was induced through heat, tissue cleaning agent, ethanol and water. To unmask 
antigen binding sites, slides were boiled in 0.01 M citrate buffer pH 6.0 for 20 minutes. 
Endogenous peroxidase activity was blocked by incubating slides in 3% hydrogen peroxide 
(H2O2) in 100% Methanol (MeOH) for 30 minutes. The sections were then incubated at room 
temperature for 30 minutes in 10% goat serum to block nonspecific binding and incubated 
overnight at 4°C in a humidified chamber with an antibody against IL-1β (Abcam, Cambridge, 
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MA) diluted 1:50 in Tris Buffered Saline with 0.2% Tween (TBS-T) containing 4% goat serum. 
Then, the slides were incubated for 30 minutes at room temperature in a humidified chamber with 
a biotinylated goat anti-rabbit IgG-B antibody diluted 1:200 in TBS-T. These slides were 
subsequently placed in streptavidin-horseradish peroxidase for 30 minutes at room temperature in 
a humidified chamber, then incubated with 50 μL of diaminobenzadine (BioGenex, San Ramon, 
CA) as a substrate, counterstained with hematoxylin (Sigma-Aldrich, Saint Louis, MO), 
dehydrated, and fixed with Permount histological mounting medium (Fisher Scientific, Hampton, 
NH). 
2.6 Urinary Protein and Albumin Measurements 
Total urinary protein excretion was determined spectrophotometrically using a Bradford 
assay. Determination of urinary albumin was analyzed by a commercially available albumin 
Enzyme-Linked Immunosorbent Assay (ELISA) kit (Bethyl Laboratories, Montgomery, TX). The 
procedure for processing of albumin followed the instructions from the manufacturer. Briefly, 
using an anti-rat albumin coated 96 well plate. The plate was washed 4 times in prepared wash 
solution provided in kit, then incubated with an anti-albumin detection antibody urine samples 
were diluted 1:200 in 1X dilution buffer and incubated for 1 hour at room temperature and exposed 
to horseradish peroxidase (HRP) color substrate. Absorbance was analyzed by a microplate reader 
using Gen5 software (BioTek, Winooski, VT).  
2.7 Glomerular Morphological Examinations  
Glomerular structure was examined using fixed paraffin-embedded kidneys, stained with a 
Periodic-Acid Schiff (PAS) stain. Glomeruli were scored on a scale of 0-4 depending on the extent 
of sclerotic changes. In general, 50 glomeruli were counted under the microscope, 0 represents no 
lesion, 1 represents sclerosis <25% of the glomerulus while 2, 3 and 4 represent sclerosis of 25% 
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to 50%, >50% to 75%, and >75% of the glomerulus respectively. A whole kidney average sclerosis 
index was obtained by averaging scores from counted glomeruli. This observation was examined 
by 2 investigators and averaged under blind conditions. 
2.8 Cellular Protein Homogenates 
Cultured podocytes were washed three times with ice-cold PBS and scraped in ice-cold 
sucrose buffer (20 mM Tris-HCl, 250 mM sucrose, pH 7.2). Cellular extract was transferred into 
a pre-chilled microcentrifuge tube and sonicated 3 times using a handheld sonicator for 10 pulses 
on ice. Samples were incubated on ice for 30 minutes prior to centrifugation at 7,000 x g for 10 
minutes at 4ºC to remove cellular debris. The supernatant was transferred to a new, pre-chilled 
microcentrifuge tube and stored at -80ºC until used for biochemical analysis. Protein 
concentrations were determined by the Braford Reagent Protein Assay method.  
2.9 Western blot analysis 
Expression levels of Vav2 were quantified in cultured mouse podocytes. Equal amounts of 
protein samples were loaded onto a prepared 8% polyacrylamide gel and allowed to separate 
electrophoretically at 120 Volts for 1 hour. Proteins from the gel were transferred onto 
polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA) using a Mini Trans-Blot® 
Electrophoretic Transfer Cell (Bio-Rad, Richmond, CA). Non-specific binding sites on the 
membranes were blocked in 5% fat-free milk made in TBS-T for 1 hour at room temperature. The 
PVDF membrane was then probed using a specific antibody against Vav2 and incubated at 4oC 
overnight.  The primary antibody used was mouse monoclonal anti-Vav2 (Santa-Cruz, Santa Cruz, 
CA) diluted 1:1000. Membranes were washed three times for 10 minutes in TBS-T and incubated 
with anti-mouse IgG-HRP (Santa Cruz, Santa Cruz, CA) for 1 hour, diluted 1:10,000 in TBS-T. 
The membranes were then washed in TBS-T for 15 minutes three times, exposed to Super Signal 
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West Pico Substrate Solution (Thermo Scientific, Rockford, IL) and protein bands were developed 
by exposure to X-Ray film. The intensity of the protein bands were quantified by densitometry 
using ImageJ Software. 
2.10 RNA Isolation and Real Time RT-Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from podocytes using TRIzol reagent (Thermo Fisher, Waltham, 
MA) according to the protocol described by the manufacturer. The resultant RNA was resuspended 
in RNase-free water and messenger RNA (mRNA) levels for Vav2 were analyzed by quantitative 
reverse transcription using a Bio-Rad iCycler system (Bio Rad, Hercules, CA). The mRNA was 
reverse transcribed to complementary DNA (cDNA) using an iScript cDNA synthesis kit (Bio 
Rad). Real-time polymerase chain reaction (RT-PCR) was performed using a SYBR supermix kit 
(Bio Rad) for 40 cycles at 95 ºC for 15 seconds and 53°C for 45 seconds. PCR efficiency was 
examined by serially diluting the template cDNA and the melting curve data were collected to 
check the PCR specificity. The mRNA levels of each sample for each gene were normalized to 
that of β-Actin. The specific primers for Vav2 based on the core sequence of rat Vav2 cDNA 
(Accession number XM_216030) were 5'- GTT CAA ACT CGG AAG TCA GG -3' (Forward) 
and 5' CCA CGG GTA TGC AGT GTA AT -3' (Reverse).  
2.11 Caspase-1 Activity, IL-1β Production and Vascular Endothelial Growth Factor (VEGF) 
Measurements 
Caspase-1 activity (Biovision, Mountain View, CA) was measured by a commercially 
available colorimetric assay. IL-1β production (R&D Systems, Minneapolis, MN) and VEGF 
(Bender Medsystems, San Diego, CA) were quantified through an ELISA using cellular 
supernatant, according to manufacturer’s instructions. 
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2.12 Rac-1 GTPase Activation Assay 
A GTPase Linked Immunosorbent Assay (GLISA) was performed to determine Rac-1 
activation in vitro (Cytoskeleton, Denver, CO). Podocytes were lysed in provided lysis buffer and 
clarified to remove cellular debris by centrifugation at 10,000 x g for 1 minute at 4°C. Equalized 
amounts of protein (1 mg/mL) was loaded onto a Rac-1 GTP affinity plate for 30 minutes. 
Following incubation, the plate was washed in wash buffer then incubated with primary and 
secondary antibodies against Rac-1. The activated Rac-1 was determined after exposure to HRP 
detection reagents by measuring absorbance at 490 nm using a microplate spectrophotometer. 
2.13 Electron Spin Resonance (ESR) Spectrophotometry of O2.- Production 
Cellular protein samples were prepared by using modified Kreb's-Hepes buffer containing 
deferoximine (100µM) and diethyldithio-carbamate (5 µM). NOX-dependent O2
.- production was 
examined by addition of 1 mM NADPH as a substrate in 30 µg protein in the presence or absence 
of superoxide dismutase (SOD) (800 U/ml), and then supplied with 10 mM O2
.- specific spin 
trapping compound, 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrro-lidine (CMH). The 
mixture was loaded in glass capillaries and immediately analyzed for O2
.-  production kinetically 
for 10 min in an ESR spectrometer. Results were obtained by subtracting the total CMH signal 
without SOD, representing the SOD-specific signal. All values were expressed as the fold change 
from control. 
2.14 Statistical Analysis 
All data are represented as mean + standard error (SE); n represents the number of 
independent experiments unless otherwise stated. Differences in mean values within and between 
multiple groups were analyzed using one-way analysis of variance (ANOVA) followed by 
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Dunnett’s post hoc test. The statistically significant differences were also assessed by applying the 
unpaired Student’s t test and the significance level was p<0.05.  
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CHAPTER THREE 
Contribution of guanine nucleotide exchange factor Vav2 to homocysteine-induced NLRP3 
inflammasome activation in mouse podocytes during hyperhomocysteinemia 
3.1 Rationale and Hypothesis  
One of critical steps for NOX to induce glomerular injury may be due to activation of the 
NLRP3 inflammasome, which senses the overall integrity and health of the cell. As illustrated in 
Figure 3, the present study hypothesized that activation of Vav2 through elevated Hcys accelerates 
the switch from GDP to GTP, thereby enhancing NOX-mediated activity and O2
.- production, 
which may instigate the cascade to glomerular sclerosis by activation of the NLRP3 inflammasome 
in podocytes. To test this hypothesis, we first used 8 week old uninephrectomized mice on a 
C57BL/6 background to examine the molecular participation of Vav2 in the actions of NLRP3 
inflammasome formation and activation which results in glomerular inflammatory responses and 
functional alterations in the glomerulus of hyperhomocysteinemic mice. Additionally, we explored 
the molecular mechanisms by which Hcys results in an active Rac-1-NOX complex using cultured 
murine podocytes. 
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Figure 3. Representative schematic illustrating the goals of Aim 1 and 2. 
Through genetic inhibition of Vav2 both in vivo and in vitro, Aims 1 and 2 will explore the 
effects of Vav2 during hHcys. 
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3.2 Results 
 
3.2.1 Confirmation of hHcys-induced Model 
Using HPLC analysis, we found that plasma Hcys concentrations was similar in all that 
consumed the ND. However, we observed increased plasma Hcys levels in FF-fed Scram-, Vav2 
shRNA- and oncoVav2-transfected mice, indicating a successful establishment of hHcys and that 
Vav2 is not involved in Hcys metabolism (Figure 4).  
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Figure 4. Effect of normal and FF diets on plasma Hcys concentrations. 
Plasma Hcys levels measured by HPLC in 6 groups of mice (n=4). Scram: Scramble, Vav2sh: 
Vav2 shRNA, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND. 
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3.2.2 In vivo inhibition of Vav2 prevented glomerular NLRP3 inflammasome formation 
and activation 
Using a hyperhomocysteinemic mouse model, we tested whether Vav2 facilitates hHcys-
induced inflammasome formation and glomerular injury. By confocal microscopy, we found that 
hHcys and oncoVav2 transfected mice fed a normal or FF diet exhibited increased colocalization 
of NLRP3 with ASC and NLRP3 with caspase-1 (Figure 5). However, this colocalization was 
inhibited in mice transfected with Vav2 shRNA (Figure 5). The summarized data is shown in 
Figures 5C and 5D. Since activation of the NLRP3 inflammasome is associated with the 
maturation of the pro-inflammatory cytokine, IL-1β, we measured the IL-1β levels in mouse 
glomeruli using immunohistochemistry. We detected a significant increase in IL-1β levels in 
hHcys mice and mice receiving the oncoVav2 plasmids on both normal and FF diets (Figure 6A). 
However, blockade of Vav2 abolished further increases in hHcys-induced glomerular IL-1β 
(Figure 6A). This data indicates that Vav2 is involved in both assembling and activation of the 
NLRP3 inflammasome in glomeruli of mice with hHcys, which could be mimicked by 
overexpression of Vav2.  
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Figure 5. Inhibition of Vav2 abolished glomerular NLRP3 inflammasome formation 
in mouse kidney. 
A-B. Colocalization of NLRP3 (green) with ASC (red) or caspase-1 (red) in mouse 
glomeruli fed a normal or FF diet. C-D. Summarized data showing the fold changes in PCC 
for the colocalization of NLRP3 with ASC or with caspase-1 (n=6). Scram: Scramble, 
Vav2sh: Vav2 shRNA, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on 
ND; # p<0.05 vs. Scram on FF Diet. 
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Figure 6. Vav2 overexpression induced NLRP3 inflammasome activation in podocytes of 
the mouse kidney.  
A. Representative images of immunohistochemical staining of IL-1β in glomerular podocytes 
in mice on the normal or FF diet. B. Summarized data depicting relative intensity of IL-1β brown 
staining (n=5). Scram: Scramble, Vav2sh: Vav2 shRNA, ND: Normal Diet and FF: Folate-Free 
Diet. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on FF Diet. 
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3.2.3 Glomerular protection by Vav2 inhibition 
It is well recognized that protein in the urine is a hallmark of many glomerular diseases. After 
a 24-hour urine collection, protein and albumin levels were evaluated in collected mouse urine to 
serve as an indicator of glomerular injury. As illustrated in Figures 7A and 7B, the FF diet 
produced both proteinuria and albuminuria in scramble sRNA-transfected mice, and the increased 
urinary excretion of protein and albumin was also observed in oncoVav2 transfected mice on a 
ND. However, this glomerular damage was attenuated in mice receiving intrarenal Vav2 shRNA 
transfection (Figures 7A and 7B). Furthermore, this glomerular dysfunction was correlated to 
modifications in the glomerular architecture as shown by morphological examinations. It was 
found that scramble sRNA and oncoVav2 plasmid-transfected mice fed a FF diet developed 
increased sclerotic damage to their glomeruli, as shown by mesangial expansion, fibrosis and 
hypercellularity with an increased glomerular damage index (GDI) (Figures 7C and 7D). 
Inhibition of Vav2 by shRNA protected mice from this glomerular sclerotic pathology. 
Immunofluorescence analysis demonstrated that the expression of podocin decreased in oncoVav2 
transfected mice on either the ND or the FF diet, but this decrease in podocin levels was not seen 
in Vav2 shRNA transfected mice on the same diet (Figure 8A). In contrast, the levels of desmin, 
a marker of podocyte injury, increased in oncoVav2 transfected mice, but not in Vav2 shRNA 
transfected mice (Figure 8B). Furthermore, as shown in Figure 8C, Vav2 protein levels were 
significantly lower in scramble sRNA and Vav2 shRNA transfected mice, as depicted by green 
staining. Figure 8D showed the relative intensity of Vav2 staining in oncoVav2 transfected mice, 
which exhibited a two-fold increase in comparison to that seen in scramble sRNA transfected mice. 
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Figure 7. In vivo inhibition of Vav2 attenuated hHcys-induced glomerular damage. 
Urinary protein (A) (n=4) and albumin (B) (n=5) measurements in 24 hr urine samples of hHcys 
mice receiving shRNA- and onco-Vav2 transfection. C. Microscopic microphotograph of 
glomerular structure in PAS stained kidney sections. D. Semiquantitative assessment of 
glomerular damage index (GDI) from PAS images (n=4). Scram: Scramble, Vav2sh: Vav2 
shRNA, ND: Normal Diet, FF: Folate-Free Diet, U: Urinary, and GDI: Glomerular Damage 
Index. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on the FF Diet. 
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Figure 8. Glomerular dysfunction associated with overexpressed Vav2 in mouse glomeruli.  
A. Florescent staining of podocyte markers, podocin (A) and desmin (B) in mouse glomeruli (n 
= 5). C. Confirmation of Vav2 (green) expression in glomerular podocytes. D. Quantification of 
relative intensity of Vav2 in glomeruli (n=4). Scram: Scramble, Vav2sh: Vav2 shRNA, ND: 
Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND; # p<0.05 vs. Scram on the 
FF Diet. 
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3.2.4 Analysis of Vav2 expression in mouse podocytes 
To verify efficiency of the Vav2 gene podocytes were co-transfected with the appropriate 
plasmid encoding for either Vav2 shRNA or oncoVav2 with an amplified green fluorescent protein 
(GFP) vector to visualize the transfected podocyte density.  In Figure 9, representative images 48 
hours-post transfection depict an intense stable gene expression in each group of transfected cells. 
Using genetic manipulations, we observed Vav2 cellular protein levels (Figure 10B) and mRNA 
expression (Figure 10C) were significantly increased 48 hours-post transfection of oncoVav2.  
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Figure 9. Determination of podocyte density 48 hours post-transfection 
A. Representative images of podocytes 48 hours post-transfection, displaying fluorescence, light 
and merged overlay (n=4). Scram: Scramble and Vav2sh: Vav2 shRNA. 
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Figure 10. Vav2 gene efficiency.  
A. Western blot gel document and summarized data (B). C. RT-PCR detection of Vav2 mRNA 
levels after shRNA and oncoVav2 transfection. (n=4)  Scram: Scramble, Vav2sh: Vav2 shRNA, 
sh: Vav2 shRNA, onco: oncoVav2 and kDA: kiloDalton. * p<0.05 vs. Scram. 
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3.2.5 Role of Vav2 in Hcys-induced NLRP3 inflammasome formation in podocytes 
The glomerulus is comprised of specialized cells that operate in a partnership to preserve the 
integrity of the kidney. Evidence strongly links podocyte injury to the pathogenesis of many 
glomerular diseases 143,144.  To better understand the impact of glomerular dysfunction during 
hHcys, we chose to further investigate the molecular mechanisms initiating injury in podocytes by 
employing cultured podocytes. Our initial studies determined if Vav2 is involved in Hcys-induced 
inflammasome formation in these cells. By confocal microscopic analysis, we detected increased 
colocalization of NLRP3 with ASC or caspase-1 in Hcys-treated podocytes when compared with 
untreated cells (Figure 11). However, this Hcys-induced increase in colocalization was inhibited 
in podocytes transfected with Vav2 shRNA (Figure 11). Additionally, oncoVav2 overexpression 
increased colocalization of inflammasome molecules in both control and Hcys-treated groups of 
podocytes. The quantitative colocalization of NLRP3 with ASC or caspase-1 is summarized in 
Figures 11C and 11D.  
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Figure 11. Hcys treatment and oncoVav2 transfection increased NLRP3 inflammasome 
formation in podocytes.  
A-B. Confocal images signifying the colocalization of NLRP3 (green) with ASC (red) and 
NLRP3 (green) with caspase-1 (red) in cultured podocytes transfected with Vav2sh or 
oncoVav2. C-D. Summarized data showing the fold change in PCC colocalization (n=6). Scram: 
Scramble, Vav2sh: Vav2 shRNA and Ctrl: Control. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys. 
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3.2.6 Activation of the NLRP3 inflammasome in vitro 
We confirmed the role of Vav2 in Hcys-induced inflammasome activation by measuring the 
levels of active or cleaved caspase-1 and the level of secreted IL-1β. As shown in Figure 12, Hcys 
treatment increased caspase-1 activity and IL-1β production in comparison to control podocytes. 
Hcys-induced increase in caspase-1 activity and elevation in IL-1β levels were significantly 
attenuated in podocytes transfected with Vav2 shRNA (Figure 12). Transfection with oncoVav2 
mimicked the effects of Hcys which increased caspase-1 activity and elevated IL-1β levels in 
cultured podocytes (Figure 12). 
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Figure 12. In vitro induction of NLRP3 inflammasome activation in podocytes, 
independent of Hcys treatment.  
A. Caspase-1 activity, shown as fold vs. Ctrl, measured in transfected podocytes treated with 
Hcys (n=5). B. IL-1β production measured in the supernatant of transfected podocytes treated 
with Hcys (n=6). Scram: Scramble; Vav2sh: Vav2 shRNA. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys. 
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3.2.7 Inhibition of Vav2 improves podocytes damage 
We further assessed the participation of Vav2 in podocyte dysfunction induced by Hcys. It 
was found that upon stimulation with Hcys, there was decreased staining of the podocyte marker 
podocin in Hcys-treated and oncoVav2-transfected podocytes, whereas desmin levels increased in 
these groups, suggesting damage to podocytes (Figure 13A). However, Vav2 shRNA reversed 
Hcys-induced podocyte damage (Figure 13A). Additionally, we observed that Hcys treatment and 
oncoVav2 transfection resulted in significant impairment of podocytes to secrete vascular 
endothelial growth factor (VEGF), a major product of healthy and mature podocytes (Figure 13B). 
Inhibition of Vav2 protected podocytes from such injury or dysfunction, which was seen by 
restored levels of VEGF secretion (Figure 13B). 
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Figure 13. NOX activation by Vav2 overexpression promoted podocyte dysfunction.  
A. Podocin (red) and desmin (blue) staining following Hcys treatment (n = 5). B. Measurement 
of secreted VEGF in cellular supernatant (n=7). Scram: Scramble; Vav2sh: Vav2 shRNA; 
Vav2si: Vav2 siRNA, * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys. 
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3.2.8 Effect of Rac-1 activation on Hcys-induced NOX activity 
It is well-defined that activated Rac serves as an anchor protein to regulate NOX activity in 
many cell types 145–147. We have shown that Hcys treatment and oncoVav2 transfection resulted in 
increased Rac-1 activation in cultured podocytes (Figure 14A). A significant decrease in Rac-1 
activity was observed in podocytes with silenced Vav2 gene, suggesting that more Rac-1 remains 
in the GDP-bound or inactive state (Figure 14A). Coupled with increased GTP-bound Rac-1, we 
also found that oncoVav2 transfection produced a great increase in O2 .-, which was inhibited in 
the Vav2 shRNA transfected podocytes (Figure 14B). 
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Figure 14. Vav2 blockade prevented in vitro inhibition of NOX-derived O2.- production. 
A. Rac-1 activity (n=6) and O2
.- production (n=5) (B) in Vav2- and oncoVav2-transfected 
podocytes in the presence or absence of Hcys. * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.  
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3.3 Summary 
In summary, the results from these experiments signify that Vav2 is critically involved in 
Hcys-induced NLRP3 inflammasome formation and activation, which may critically contribute to 
podocyte dysfunction and glomerular injury. These results demonstrate that Rac-1-NOX activation 
and subsequent production of O2 
.- are main triggering mechanisms of the NLRP3 inflammasome 
in podocytes, which is consistent with previous reports 56,94. Vav2 may be a therapeutic target for 
termination of early events in hyperhomocysteinemic nephropathy and ESRD. 
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CHAPTER FOUR 
Pharmacological targeting of Vav2 to inhibit the NLRP3 inflammasome and glomerular 
injury during hHcys 
4.1 Rationale and Hypothesis  
We have established that Vav2 signaling initiates a pathogenic mechanism facilitating 
hHcys-induced glomerular injury by activation of the NLRP3 inflammasome. This multi-protein 
complex has been shown to elicit direct damaging insults both inflammatory and non-
inflammatory, suggesting that its activation may turn on glomerular inflammation and other 
cellular damages, contributing to the onset of glomerular injury and ESRD. We have shown from 
the chapter above that Vav2 is functionally required to initiate the progression of these downstream 
signaling events, indicating that targeting of Vav2 signaling could potentially serve as an 
innovative therapeutic to halt glomerular damage associated with hHcys (Figure 15). To test this 
hypothesis, we administered pharmacological interventions of Vav2 signaling to glomerular 
epithelial cells and Nlrp3-/- mice. 
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Figure 15. Representative schematic illustrating the goal of Aim 3.  
Aim 3 will investigate the targeting of Vav2, pharmacologically to prevent or treat hHcys-
induced inflammasome activation and glomerular injury. 
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4.1 Results  
4.2.1 Rac-1 inhibition by NSC23766 ameliorated Hcys-induced inflammasome activation and 
podocyte injury in vitro  
To determine whether targeting of Vav2 can prevent excessive NLRP3 inflammasome 
signaling during Hcys-induced injury, podocytes were treated with either uridine triphosphate 
(UTP), a Vav2 activator or NSC23766, a selective inhibitor of Rac-1 in the presence or absence of 
Hcys. As depicted in Figure 16, pretreatment of podocytes with UTP and Hcys resulted in a 
significant elevation of GTP-bound Rac in comparison to untreated cells. However, NSC23766 
treatment blocked Hcys-induced Rac GTPase activity. By confocal microscopy, we demonstrated 
that following Hcys treatment, podocytes increased colocalization of NLRP3 with ASC or caspase-
1 in comparison to control cells (Figures 17A and Figure 17B). Stimulation of podocytes with 
UTP, mimicked this Hcys-induced inflammasome formation and had no further enhancing effects 
on Hcys response (Figures 17A and Figure 17B). Pretreatment with NSC23766, blocked Hcys-
induced increases in inflammasome formation as shown by reduced NLRP3 colocalization with 
ASC or caspase-1 (Figure 17A and Figure 17B).  Using caspase-1 activity and IL-1β production 
as indicators of NLRP3 inflammasome activation, we found increased activation of caspase-1 in 
Hcys-treated podocytes, and prior treatment of podocytes with NSC23766 led to attenuated 
caspase-1 levels (Figure 18A). Similar to Hcys, UTP treatment increased the level of cleaved 
caspase-1 (Figure 18A). Elevated production of IL-1β displayed in Hcys- and UTP treated 
podocytes, signifying inflammasome activation (Figure 18B). Inhibition of Rac-1, by pre-
incubation of NSC23766 reduced IL-1β production in Hcys-induced podocytes (Figure 18B). 
During glomerular podocyte maturation, VEGF is secreted from the cell and is an essential 
molecule necessary for podocyte survival and function. We observed in both Hcys- and UTP-
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injured podocytes VEGF secretion was significantly reduced in comparison to control cells 
(Figure 19). Additionally, prior treatment with NSC23766 resulted in increased secretion of 
VEGF, indicating preserved podocyte function (Figure 19).   
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Figure 16. NSC23766 attenuated Hcys-induced Rac-1 activation.  
A. Rac-1 activity in UTP-and NSC23766-treated podocytes (n=3).Vehl: Vehicle and NSC: 
NSC23766, * p<0.05 vs. Ctrl; # p<0.05 vs. Hcys. 
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Figure 17. Rac-1 Inhibition prevented Hcys-induced NLRP3 inflammasome formation.  
Confocal microscopy analysis of NLRP3 (green) with ASC (red) (A) and NLRP3 (green) with 
caspase-1 (red) (B) in treated podocytes. C-D. Summarized data showing the quantification of 
colocalization of inflammasome components (n=3). Vehl: Vehicle and NSC: NSC23766, * 
p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.  
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Figure 18. Inhibition of Vav2 attenuated Hcys-induced NLRP3 inflammasome activation. 
Effect of inhibition of Vav2 on caspase-1 activity (A) and IL-1β production (B) induced by Hcys 
in podocytes treated with  UTP or NSC23766 (n=6). Vehl: Vehicle and NSC: NSC23766, * 
p<0.05 vs. Ctrl; # p<0.05 vs. Hcys.    
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Figure 19. Blockade of Vav2 signaling maintained podocyte function. 
A. Measurement of VEGF secretion as a podocyte function parameter was detected in the 
supernatant of treated podocytes (n=6). Vehl: Vehicle and NSC: NSC23766, * p<0.05 vs. Ctrl; 
# p<0.05 vs. Hcys.    
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4.2.2 Mouse Nlrp3 gene deletion and Vav2 inhibition prevented hHcys-induced NLRP3 
inflammasome formation and activation in glomeruli 
To further determine whether targeting of Vav2 signaling attenuates hHcys-induced NLRP3 
inflammasome formation and activation in vivo, Nlrp3-/- (KO) and Nlrp3+/+ (WT) mice were 
administered UTP or NSC23766, intraperitoneally and fed either a ND or FF diet for 4 weeks. 
Approximation of plasma Hcys concentration was evaluated by HPLC. In both KO and WT mice 
consuming the FF diet significantly increased total Hcys levels in comparison to their ND-fed 
littermates (Figure 20). Neither gene deletion nor treatment with UTP or NSC23766 altered Hcys 
levels. As shown in Figures 21, hHcys Nlrp3+/+ mice as well as those mice administered UTP 
displayed increased inflammasome formation seen by colocalization of inflammasome 
components, NLRP3 with ASC and NLRP3 with caspase-1 as well as increased IL-1β production 
in the glomeruli, indicating inflammasome activation (Figure 22). However, this formation and 
activation was inhibited in hHcys Nlrp3-/- mice and mice receiving NSC injections (Figure 21 and 
Figure 22). The summarized data of quantitative colocalization of NLRP3 with ASC or with 
caspase-1 in glomeruli of mice were shown in Figures 21C and 21D. 
   
  
 
69 
 
 
 
Figure 20. Effects of gene knockout or in vivo UTP and NSC23766 administration on FF 
diet-induced Hcys concentration.  
A. Plasma Hcys levels measured by HPLC in Nlrp3-/- and Nlrp3+/+ mice (n=1-7). Vehl: Vehicle, 
NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Vehl on ND. 
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Figure 21. HHcys and UTP administration induces NLRP3 inflammasome formation. 
Colocalization of NLRP3 (green) with ASC and NLRP3 with caspase-1 (red) in mouse 
glomeruli following UTP or NSC23766 administration in FF- or ND-fed mice (n=3). Vehl: 
Vehicle, NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on 
ND. * p<0.05 vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet. 
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Figure 22. In vivo administration of NSC23766 attenuated NLRP3 inflammasome 
activation. 
A. Immunohistochemical staining of IL-1β in glomerular podocytes (n=2). Vehl: Vehicle, NSC: 
NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram on ND. * p<0.05 
vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet. 
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4.2.3 Administration of NSC23766 protected glomerular podocytes from hHcys-induced 
dysfunction and injury 
To assess whether inflammasome-mediated glomerular damage is a consequence associated 
with podocyte dysfunction we determined the expression levels of podocyte specific markers, 
podocin and desmin by immunofluorescence analysis. Our results displayed that in both hHcys 
Nlrp3+/+ mice and UTP-treated mice there was dramatic decreases in podocin staining (Figure 
23A). Rac-1 inhibition by NSC23766 administration resulted in ameliorated hHcys-induced 
glomerular damage shown by restoration of podocin expression levels (Figure 23A). Moreover, 
Nlrp3+/+ UTP treated mice exhibited a high abundance of desmin expression in glomeruli of both 
ND and FF-fed groups, whereas NSC23766 administration protected against hHcys-induced 
increases in glomerular desmin in Nlrp3+/+ mice, with similar expression levels as the Nlrp3+/+ mice 
on a ND (Figure 23B). 
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Figure 23. NSC23766 protected glomerular podocytes from dysfunction.  
Immunofluorescent staining of podocin (A) and desmin (B), podocyte-specific markers (n=3). 
Vehl: Vehicle, NSC: NSC23766, ND: Normal Diet and FF: Folate-Free Diet. * p<0.05 vs. Scram 
on ND. * p<0.05 vs. Vehl on ND; # p<0.05 vs. Vehl on the FF diet. 
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4.3 Summary 
Taken together, our results demonstrate that blockade of Vav2 exchange activity diminished 
NLRP3 inflammasome formation and activation in vitro and in vivo. Additionally, inhibition of 
the NLRP3 inflammasome protected podocytes from the early adverse effects of increased Hcys, 
demonstrating that tight regulation of the NLRP3 inflammasome by intervention of Vav2 
activation could prevent unwarranted damage and excessive inflammation seen in hHcys-
associated glomerular injury. 
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CHAPTER FIVE 
DISCUSSION 
 
5.1 Activation of NADPH oxidase by Vav2 overexpression is sufficient to activate the NLRP3 
inflammasome in glomerular podocytes, independent of hHcys 
The primary goal of this study was to reveal the involvement of the GNEF, Vav2 in activation 
of the NLRP3 inflammasome during hHcys. Our results showed that Vav2 inhibition by RNA 
interference attenuated hHcys-induced NLRP3 inflammasome formation and activation in 
podocytes. Conversely, overexpression of Vav2 resulted in enhanced inflammasome formation 
and activation in these cells independent of Hcys treatment. Results from the present study also 
demonstrated that Vav2 inhibition protected podocytes against Hcys-induced glomerular injury. 
This Vav2-mediated action was associated with NOX activation and increased ROS production in 
glomeruli.   
Distinctive GNEFs facilitate the conversion of GDP for GTP, inciting Rho protein activation 
148. Among more than 100 GNEFs, the Vav subfamily is highly selective in coordinating 
intracellular signal transduction pathways associated with NOX activation 141,149. Our earlier 
studies have demonstrated that of 3 Vav isoforms, both Vav2 and Vav3 are localized in the 
glomeruli, whereas it is already established in other reports that Vav1 is solely present in 
hematopoietic cells 48. We have shown that by sensing intracellular ROS during hHcys, 
thioredoxin-interacting protein (TXNIP) associates with NLRP3 to trigger the cascade of 
downstream events leading to inflammasome activation 56. Recently, evidence links Vav2 as a 
binding partner of TXNIP 150. Therefore, we sought to identify whether the detrimental actions of 
Vav2 are involved in NLRP3 inflammasome assembling, activation and subsequent podocyte 
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dysfunction. It has been reported that internal or external danger signals are capable of initiating 
the recruitment of ASC and caspase-1 forming the NLRP3 inflammasome complex 2,50. This 
inflammasome complex triggers the production of IL-1β and IL-18, inducing a heightened 
inflammatory response. Processing of not only the interleukins, but also caspase-1 is considered 
crucial in the inflammatory process that leads to tissue injury, organ or systemic diseases 96. In 
particular, NLRP3 inflammasome activation has been implicated in the pathogenesis of various 
renal diseases including acute kidney injury, chronic kidney disease, diabetic nephropathy, crystal 
related nephropathy and hyperhomocysteinemic nephropathy 3,151,152. Renal cells such as 
podocytes have been documented as the main enriched sites for maturation of glomerular IL-1β 
production 43,107.  
To our knowledge, we are the first to report that silencing the Vav2 gene and reduction of its 
activity using genetic manipulations inhibited the NLRP3 inflammasome by preventing the 
activation of the small GTPase, Rac-1. Consistent in both our in vivo and in vitro models, our 
results show that Vav2 shRNA interventions decreased the interactions of inflammasome 
components NLRP3, ASC and caspase-1 (Figures 5 and 11). Consequently, the absence of 
inflammasome machinery resulted in decreased IL-1β production in mouse glomeruli (Figure 6) 
which was associated with diminished caspase-1 activity in podocytes (Figure 12). The most 
remarkable finding in the present study was that Vav2 overexpression triggered NLRP3 
inflammasome formation irrespective of Hcys exposure (Figure 5 and 11), suggesting that Vav2 is 
crucial in bridging the redox signals derived from NOX activity and NLRP3 inflammasome 
activation, which may be a critical mechanism responsible for glomerular inflammatory response 
during hHcys.  
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There is evidence that abundance of protein leaked in the urine and excessive reabsorption 
of protein in renal proximal tubular cells are linked to the pathophysiological states of renal disease 
development 153,154. In this regard, Connell et al. demonstrated that in response to albumin 
overloads, proximal tubule cells encounter direct toxic effects associated with Rac GTPase and 
NOX activation as well as receptor-mediated endocytosis 155. Our results add to this by showing 
that mice with overexpressed Vav2 had typical features of glomerular damage as evidenced by 
proteinuria, albuminuria and increased GDI (Figure 7). Downregulation of the Vav2 gene 
effectively ameliorated these detrimental effects in mouse glomeruli. With respect to the 
mechanism of glomerular injury during different pathological conditions such as hHcys, podocyte 
injury is considered to play an important role. It has been reported that disruption of the slit 
diaphragm, actin rearrangement and foot process effacement are unique indicators of podocyte 
injury 143,156. Our data revealed that Hcys treatment and Vav2 overexpression decreased a 
podocyte-specific molecule, podocin (Figure 8 and 13), which may result in derangement of the 
slit diaphragm structure and related cell signaling pathways 156. Furthermore, resultant injury to 
podocytes may lead to the upregulation of the intermediate filament, desmin, which was indeed 
confirmed in our studies as shown by increased desmin levels in podocytes during hHcys or 
exposure to high levels of extracellular Hcys. Interestingly, this desmin increase in podocytes 
during hHcys could be blocked by shRNA of Vav2, but mimicked by oncoVav2 transfection. The 
results suggest that Vav2 critically contributes to hHcys-induced podocyte injury and glomerular 
sclerosis.  
To explore the mechanisms by which Vav2 activates the NLRP3 inflammasome and thereby 
lead to podocyte injury and glomerular sclerosis, we examined the effects of Vav2 interventions 
on Rac activity and consequent NOX activation. It is well known that instigation of NOX as a 
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functional signaling complex is dependent on the translocation of its cytosolic subunits (p47phox 
and p67phox) to the membrane in which this platform initiates the generation of superoxide (O2 .-) 
25,157. The Rac protein is crucial in these migratory events, serving as a binary switch that cycles 
between active GTP-bound and inactive GDP-bound states. However, the molecular cues directly 
responsible for Rac protein activation and subsequent NOX activity following prolonged exposure 
to Hcys remained unclear. From our findings, we confirm that expression of constitutively active 
Vav2, can itself drive the activation of the Rac-1 protein (Figure 14A) and the aggregation of a 
functional NOX complex, which produces O2 .- even without Hcys stimulus (Figure 14B). 
Moreover, blockade of Vav2 attenuated enhancement of Rac activity and O2 .- generation, even in 
the presence of Hcys, a known activator of ROS. Results from these experiments illustrate that 
Vav2 can promote injurious consequences in podocytes and that inhibition of Vav2 function may 
terminate the development and progression of Hcys-induced podocyte injury and consequent 
glomerular sclerosis. 
5.2 Inhibition of Vav2 signaling by NSC23766 ameliorated hhHcys-induced glomerular 
dysfunction 
In the present study, we clearly demonstrated that inhibition of Vav2 exchange activity by 
administration of NSC23766 prevented upregulation of Rac-1 GTPase production in Hcys-treated 
podocytes, resulting in attenuated NLRP3 inflammasome formation, inhibition of caspase-1 
activation and a subsequent reduction in IL-1β processing and release. Additionally, we showed 
that administration of NSC23766 in vivo attenuated excessive hHcys-induced inflammasome 
activation and glomerular dysfunction, thus highlighting the significance of pharmacologically 
targeting Vav2 activity. 
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ESRD is regarded as one of the world’s most prevalent chronic disorders 7,154. Although 
many therapeutic approaches focus on slowing the progression of renal failure, alleviating the 
severity of symptoms, management of risk factors and prolonging life remain a large challenge 
clinically given that many patients in the early stages of CKD are asymptomatic. Therefore, early 
diagnosis and effective interventions are crucial in management and amelioration of kidney injury. 
We have found that the underlying mechanism associated with Hcys-induced podocyte 
dysfunction and injury is dependent on the activation of Vav2. Expression of Vav2 in podocytes 
promotes the activation of Rac-1 which leads to the aggregation of the multi-protein NOX 
complex, promoting O2
.- production, inflammasome activation and initiation of glomerular injury. 
Progression of these downstream signaling events are primary contributing factors associated with 
hHcys-induced nephropathy. It is clear that novel therapies to target Vav2 and the inflammasome 
may be an important therapeutic strategy to lessen the extent of glomerular injury.  
In our previous studies, we revealed that the Nlrp3 gene is a critical component necessary 
for assembling and corresponding injury during hHcys 158. Furthermore, we reported that chronic 
elevations of Hcys contribute to the development of glomerular disease independent of 
hypertension 159. In previous studies, Nlrp3 deficient mice have been reported to have cardio-
protective effects during myocardial ischemia 160 as well as protection against pancreatic damage 
associated with diet-induced obesity 161. Utilization of these mice in our study demonstrated 
remarkable protection against hHcys-induced inflammasome activation and glomerular injury. 
Additionally, using a Rac-1 selective inhibitor in Nlrp3+/+ mice proved to exhibit reno-protective 
effects against hHcys-induced alterations in the glomeruli. We found that these mice had 
attenuated inflammasome formation (Figure 21), enhanced podocin expression (Figure 23) and a 
downregulation of the injury marker, desmin (Figure 23). In vitro, following pretreatment of 
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glomerular podocytes with Rac-1 inhibitor, NSC23766 abolished Hcys-induced inflammasome 
formation (Figure 17) and activation (Figure 18). Through biochemical analysis we also observed 
protective effects associated with increased VEGF secretion in this group of podocytes (Figure 
19). Taken together, these results confirm that the Nlrp3 gene mediates hHcys-induced 
inflammasome formation and activation, but most significantly these findings demonstrate that 
pharmacological modification of Vav2 exchange activity abolished these pathological events 
associated with increased Hcys. 
 
5.3 Significance and perspectives 
There is indeed increasing evidence for an association between glomerular diseases and 
NLRP3 inflammasome activation, which leads to caspase-1-mediated IL-1β/IL-18 production. 
More knowledge is needed in this area to further assess the underlying relationship between the 
NLRP3 inflammasome activation and decline of glomerular function in various chronic kidney 
diseases, in particular, to define the temperospatial contribution of the activated inflammasomes 
to the onset or development of glomerular disease and ultimate ESRD. Moreover, recognition and 
clarification of the non-canonical effects of NLRP3 inflammasome activation in glomeruli as well 
as the alternative pathways to activate this inflammasome may be particularly interesting and 
important, because this non-canonical action and alternative inflammasome activating pathways 
may result in a combination of injurious actions independent of typical inflammation. Possible 
direct damage to glomerular cells, interference with synthesis of cell-specific proteins, enhanced 
cell membrane permeability and cell pyroptosis may importantly contribute to glomerular injury 
during NLRP3 inflammasome activation in response to pathological stimuli. These direct effects 
of NLRP3 inflammasome activation may suggest a new therapeutic strategy for treatment and 
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prevention of glomerular sclerosis and ESRD, namely, targeting the NLRP3 inflammasome-
mediated uncanonical mechanism responsible for glomerular injury. This therapeutic strategy may 
be more efficient for treatment or prevention of progressive chronic glomerular injury or sclerosis 
compared with the approaches that just target the inflammatory pathways.  
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